ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2021

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.

Yifat S Oren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.